Moreover, intestinal ILC3-derived IL22 might promote barrier protection via enhanced proliferation and repair of the epithelium along with production of antimicrobial peptides because IL22 in general can elicit these effects; however, IL22 stimulation has also been reported to contribute to cancer development, as evidenced from several mouse CRC, pancreatic, hepatic, and other cancer models in which IL22 expression was positively correlated to tumor burden, as reviewed recently [54,66]. Here, IL22 is linked to colorectal carcinoma.